Thermo Fisher Scientific has acquired Clario Holdings, Inc. for an undisclosed amount, marking a significant expansion in its clinical trial services portfolio. Clario is a prominent healthcare research and technology company specializing in generating high-quality clinical evidence for pharmaceutical, biotech, and medical device partners. The company delivers comprehensive evidence generation solutions, including eCOA, cardiac safety, medical imaging, precision motion, and respiratory endpoints.
With over 50 years of experience, Clario has supported more than 26,000 clinical trials across 100 countries and contributed to over 60% of all FDA drug approvals since 2019. Its deep scientific expertise and broad endpoint technologies are critical for site-based, hybrid, and decentralized clinical trials. Thermo Fisher Scientific, a global leader in serving science, provides a wide array of scientific instrumentation, consumables, and services across various life science and healthcare segments, including clinical research.
This acquisition is strategically aligned with Thermo Fisher’s commitment to providing comprehensive solutions throughout the drug development lifecycle. Clario's advanced endpoint technologies and clinical trial management solutions will complement Thermo Fisher's existing capabilities, particularly its clinical research services, by enhancing the ability to collect and analyze complex clinical data. The integration is expected to create synergies that accelerate drug development for customers by offering a more unified and robust suite of evidence generation services, from early-phase assessment to regulatory submission.
The combined entity is poised to deliver an unparalleled breadth of scientific and technological expertise to its pharmaceutical and biotech partners. This union aims to streamline clinical trial processes, improve data accuracy, and expand global reach, ultimately supporting the development of new therapies and improving patient outcomes worldwide. The acquisition solidifies Thermo Fisher's position as a critical partner in transforming clinical research and evidence generation.